Connect with us


New FDA-Cleared Vibration Belt Offers Hope for Post-Menopausal Women with Osteopenia


A breakthrough in combating bone loss among post-menopausal women has emerged with the recent FDA clearance of Osteoboost, a vibration belt designed to address low bone density. Manufactured by Bone Health Technologies, Osteoboost targets women with osteopenia, a condition characterized by reduced bone density.

Osteoboost functions by delivering low-frequency vibrations directly to the lumbar spine and hips. According to Laura Yecies, CEO of Bone Health Technologies, a study conducted at the University of Nebraska Medical Center demonstrated the belt’s effectiveness in both stimulating bone growth and keeping bone mineral density strong in postmenopausal women who suffer from osteopenia.

Despite the availability of osteoporosis medications, fewer than 10% of eligible patients utilize them, highlighting a significant treatment gap. Osteoboost offers a non-medication, home-based alternative that is safe and easy to use, potentially benefiting a wide range of patients with bone density loss.

The FDA clearance was based on NIH-funded research, with findings presented at scientific meetings by the Endocrine Society and the American Society of Bone and Mineral Research. Notably, a pivotal study led by Dr. Laura Bilek of the University of Nebraska Medical Center showcased Osteoboost’s efficacy in reducing bone loss in post-menopausal women.

Clinical Insights and Potential Impact

Dr. Chris Morris, a rheumatologist, emphasizes the therapy’s potential to improve bone density and reduce fracture risk, particularly during the menopause transition when bone loss accelerates. Osteoboost’s ability to enhance balance and mobility could further benefit individuals at risk of fractures.

While the research shows promise, further studies are needed to assess long-term fracture risk reduction and compare Osteoboost with standard medication therapies. Pricing details are pending, with plans for device shipment later this year.

Osteopenia and osteoporosis signify a loss of bone density, with osteopenia serving as a precursor to osteoporosis. Both conditions increase fracture risk, with osteopenia affecting approximately 34 million Americans.

DEXA scans, which measure bone density, aid in diagnosis, highlighting the importance of early detection and intervention in managing bone health.

In conclusion, Osteoboost represents a significant advancement in addressing bone loss among post-menopausal women, offering a convenient, non-invasive treatment option with the potential to improve quality of life and reduce fracture risk.

What do you think of this new treatment? Leave your thoughts in the comments below. 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *